Primary Prevention of Ischemic Stroke
Primary Prevention of Ischemic Stroke
Stroke is the second most common cause of death worldwide and a leading cause of long-term neurological impairment, with as many as 30% of survivors permanently disabled.1 3 Of all strokes, approximately 70% are first-time events, thus primary care physicians have a great opportunity to identify patients who may benefit from risk factor modification.2 Furthermore, neurologists frequently evaluate non-stroke patients who carry modifiable stroke risk factors. In these settings, initiation of primary prevention strategies may have the greatest impact on the disease and its enormous toll on the healthcare system.
Risk Factors of Ischemic Stroke
Numerous factors contribute to the risk of first stroke. The non-modifiable risk factors include increasing age, sex, race/ethnicity, family history, genetic factors, and low birth weight. While not modifiable, these risk factors may identify those who are at highest risk of stroke and who may benefit from aggressive treatment of any modifiable risk factors. Regarding age, each decade above 55 years of age leads to a doubling of stroke risk.4 Men carry an overall higher risk of stroke than women at younger ages, but women are at greater risk over the age of 85 years.5 This relatively greater risk in older women may reflect changing hormonal status and/or the use of hormone replacement therapy (HRT), as well as the fact that men with stroke risk factors may die earlier from cardiovascular disease.6,7 Race and ethnic contributions to stroke risk are difficult to separate from other risk factors such as hypertension and diabetes, which are more prevalent in certain populations. Even taking into account these risk factors, however, stroke incidence rates remain higher among some racial ethnic groups (e.g. African- Americans).8,9 Unidentified genetic risk factors may predispose these groups to stroke and may eventually help to explain the contribution of family history to stroke risk. Stroke is a manifestation of a variety of rare genetic disorders, but the association between most inherited coagulopathies e.g. protein C and S deficiency and arterial events is weak.10,12 Finally, stroke incidence and stroke mortality are increased among individuals with low birth weight.13,14
The long list of modifiable stroke risk factors is best separated into two groups:
" those that clearly contribute to risk and, if modified, reduce the risk of incident stroke; and " those that are associated with stroke, but have not been well studied or do not reduce the risk of stroke when treated.
Well documented risk factors that clearly benefit from specific management include hypertension, cigarette smoking, atrial fibrillation, dyslipidemia, diabetes mellitus, and asymptomatic carotid stenosis (see Table 1).15-17 The discussion and treatment of these risk factors will be the focus of this article. Other well documented risk factors are cardiovascular and peripheral arterial disease, sickle cell disease, and obesity. Less well documented or potentially modifiable risk factors include metabolic syndrome, hyperhomocysteinemia, hypercoagulability, oral contraceptive use, inflammatory processes, migraine headache, and sleep apnea, among others.18
Hypertension
Blood pressure is a powerful determinant of stroke risk and, because hypertension is the most prevalent of the modifiable stroke risk factors throughout middle and older age, its treatment would produce the greatest impact on reducing the burden of stroke.19 Recent evidencebased guidelines on management of hypertension recommend antihypertensive agents and lifestyle modification to keep blood pressure <140/90, with even tighter control recommended for those with additional vascular risk factors such as diabetes and chronic kidney disease (see Table 2).20 Overall, across multiple classes of antihypertensive therapy, blood pressure reduction is associated with approximately 30 40% reduction in the incidence of stroke, with more intensive lowering superior to less.21,22 Placebo-controlled studies have demonstrated the efficacy of thiazide diuretics, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, and calcium-channel blockers in reducing stroke and cardiovascular outcomes.21,22 In general, the choice of a particular class of agents is less important than the degree of blood pressure reduction achieved.
- Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2002,World Health Organization,World Health Report 2003: Statistical Annex 2.
- Wolf PA, et al., Neurol, 1998;4(Suppl. 4):A55 6.
- American Heart Association,Heart Disease and Stroke Statistics 2004 update, 2003.
- Wolf PA, et al., Stroke, 1992;23:1551 5.
- Sacco RL, et al., Am J Epidemiol, 1998;147:259 68.
- Kittner SJ, et al., N Engl J Med, 1996;335:768 74.
- Mosca L, et al., Circulation, 1997;96:2468 82.
- Rosamond WD, et al., Stroke, 1999;30:736 43.
- Giles WH, et al., Arch Intern Med, 1995;155:1319 24.
- Rubattu S, et al., J Cardiovasc Pharmacol, 2001;38(Suppl. 2):S71 4.
- Nicolaou M, et al., Stroke, 2000;31:487 92.
- Ortel TL, Genetics of Cerebrovascular Disease, Futura Publishing Co, 1999:129 56.
- Barker DJ, et al., Stroke, 2003;34:1598 1602.
- Lackland DT, et al., J Clin Hypertens, 2003;5:133 6.
- Wolf PA, et al., Stroke, 1991;22:312 18.
- D Agostino RB, et al., Stroke, 1994;25:40 43.
- Wang TJ, et al., JAMA, 2003;290:1049 56.
- Goldstein LB, et al., Stroke, 2006;37:1583 1633.
- Lewington S, et al., Lancet, 2002;360:1903 13.
- Chobanian AV, et al., JAMA, 2003;289:2560 72.
- Neal B, et al., Lancet, 1998;351:1755 62.
- Blood Pressure Lowering Treatment Trialists Collaboration, Lancet, 2000;355:1955 64.
- Manolio TA, et al., Stroke, 1996;27:1479 86.
- Rodriguez BL, et al., Stroke, 2002;33:230 36.
- Kurth T, et al., Stroke, 2003;34:2792 5.
- Wolf PA, et al., JAMA, 1998;259(7):1025 9.
- Kawachi I, et al., JAMA, 1993;269(2):232 6.
- Wolf PA, et al., Stroke, 1991;22(8):983 8.
- Hart RG, et al., Ann Intern Med, 1999;131:492 501.
- Gage BF, et al., JAMA, 2001;285:2864 70.
- Sportif Executive Steering Committee for the SPORTIF V Investigators, JAMA, 2005;293:690 98.
- Perez-Gomez F, et al., J Am Coll Cardiol, 2004;44:1557 66.
- The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM), N Engl J Med, 2002;347(23):1825 33.
- Zhang X, et al., Int J Epidemiol, 2003;32:563 72.
- Wannamehee SG, et al., Stroke, 2000;31:1882 8.
- Soyama Y, et al., Stroke, 2003;34:863 8.
- Shahar E, et al., Stroke, 2003;34:623 31.
- Cholesterol Treatment Trialists (CTT) Collaborators, Lancet, 2005;366:1267 78.
- Heart Protection Study Collaborative Group, Lancet, 2003;361:2005 16.
- Sever PS, et al., Lancet, 2003;361:1149 58.
- Amerenco P, et al., Stroke, 2004;35:2902 9.
- LaRosa JC, et al., N Engl J Med, 2005;352(14):1425 1535.
- Adler AI, et al., BMJ, 2000;321:412 19.
- Lindholm LH, et al., Lancet, 2002;359:1004 10.
- Calhoun HM, et al., Lancet, 2004;364:685 96.
- UK Prospective Diabetes Study (UKPDS) Groups, Lancet, 1998;352:837 53.
- UK Prospective Diabetes Study (UKPDS) Groups, Lancet, 1998;352:854 65.
- Chambers BR, et al., N Engl J Med, 1986;315(14):860 65.
- Mackey AE, et al., Neurology, 1997;48(4):896 903.
- Meissner I, et al., JAMA, 1987;258(19):2704 7.
- Executive Committee for the Asymptomatic Carotid Atherosclerosis Study, JAMA, 1995;273:1421 8.
- MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group, Lancet, 2004;36;1491 502.
- Rothwell PM, et al., Stroke, 2004;35:2425 7.
- Mas JL, et al., N Engl J Med, 2006;355(16):1660 71.
- Rossouw JE, et al., JAMA, 2002;288:321 33.
- Anderson GL, et al.,Women s Health Initiative Steering Committee, JAMA, 2004;291(14):1701 12.
- Hayden M, et al., Ann Intern Med, 2002;136:161 72.
- Steering Committee of the Physicians Health Study Research Group, N Engl J Med, 1989;321:129 35.
- Ridker PM, et al., N Engl J Med, 2005;352(13):1293 1304.
- Whisnant JP, et al., Neurology, 1996;47:1420 28.
- Bonow RO, et al., J Am Coll Cardiol, 1998;32(5):1486 1588.
- Go AS, et al., JAMA, 2001;285:2370 75.
- Wilterdink JL, et al., Arch Neurol, 1992;49:857 63.
Specialities:
- Neurology
- ADHD
- Advanced Parkinson's Disease
- Anxiety Disorder
- Brain Cancer
- Cerebrovascular Disease
- Dementia
- Epilepsy
- Mood Disorders
- Motor/Movement Disorder
- Multiple Sclerosis
- Neuroimaging
- Neurosurgery
- Obsessive-Compulsive Disorder
- Pain/Headache
- Parkinson's Disease
- Psychiatry
- Schizophrenia
- Sleep Disorder
- Stroke
- 16 February 2012
- 1 March 2012
- 1 March 2012










